Response to ASX Price Query
Released
Released
Announcement PDF
Date: 25 November 2024
Ms Melissa Kostopoulos
Senior Adviser
Listings Compliance
Response to ASX Price Query - Paradigm Biopharmaceuticals Ltd
Dear Melissa,
We refer to your letter dated 25 November 2024 wherein the ASX notes an increase in share
price of Paradigm Biopharmaceuticals Ltd (ASX: PAR) (Company) securities between close of
trade on 22 November to intra-day trading on 25 November 2024, in addition to an increase
in traded volume of securities on 25 November 2024.
The Company provides the following responses to the ASX’s queries:
ASX Question 1: Is PAR aware of any information concerning it that has not been announced
to the market which, if known by some in the market, could explain the recent trading in its
securities?
No, the Company is not aware of any information concerning it that has not been announced
to the market which, if known, could explain recent trading in the Company’s securities.
If the answer to question 1 is “yes”.
(a) Is PAR relying on Listing Rule 3.1A not to announce that information under Listing Rule
3.1? Please note that the recent trading in PAR’s securities would suggest to ASX that such
information may have ceased to be confidential and therefore PAR may no longer be able
to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is “yes”, you need to
contact us immediately to discuss the situation.
(b) Can an announcement be made immediately? Please note, if the answer to this question
is “no”, you need to contact us immediately to discuss requesting a trading halt (see below).
(c) If an announcement cannot be made immediately, why not and when is it expected that
an announcement will be made?
The Company’s response to ASX Question 1 is “No”.
AUSTRALIA (Head Office)
Paradigm Biopharmaceuticals Limited
Level 15, 500 Collins St
Melbourne, Victoria 3000
USA
Paradigm Biopharmaceuticals (USA) Inc
31 West 34th St, 8th Floor
New York, New York 10001
IRELAND
Paradigm Biopharmaceuticals (Ireland)
Limited
Fitzwilliam Hall, Fitzwilliam Place
Dublin 2
paradigmbiopharma.com | info@paradigmbiopharma.com
ASX Question 2: If the answer to question 1 is “no”, is there any other explanation for the
recent trading in its securities.
Paradigm Biopharmaceuticals has provided an update to the ASX on October 31, 2024,
announcing the submission of its revised Phase 3 clinical trial protocol to the U.S. Food and
Drug Administration (FDA). The FDA’s standard review period for such submissions is 30 days,
concluding on November 28, 2024. As of this date 25 November 2024, the company has not
received any feedback or communication from the FDA. In the absence of a response within
the designated review period, Paradigm anticipates initiating start-up activities for its Phase 3
pivotal clinical trial evaluating injectable pentosan polysulfate sodium (iPPS) as a treatment
for knee osteoarthritis (OA).
Paradigm Biopharmaceuticals also informed the ASX on October 31, 2024, that it expects a
response to its Determination Application submitted to the Therapeutic Goods Administration
(TGA) during the December quarter. This application is a critical step toward advancing the
submission for provisional approval of iPPS for the treatment of knee OA in Australia.
Achieving this determination represents significant progress in securing regulatory approval
within the region.
ASX Question 3: Please confirm that PAR is complying with the Listing Rules and, in
particular, Listing Rule 3.1.
The Company confirms it is in compliance with the ASX Listing Rules, in particular, ASX Listing
Rule 3.1.
ASX Question 4: Please confirm that PAR’s responses to the questions above have been
authorised and approved under its published continuous disclosure policy or otherwise by
its board or an officer of PAR with delegated authority from the board to respond to ASX on
disclosure matters.
The Company also confirms that the above responses have been authorised and approved
under the Company’s continuous disclosure policy and by its Board.
Authorised for release by the Paradigm board.
Sincerely,
Abby Macnish Niven
CFO & Company Secretary
AUSTRALIA (Head Office)
Paradigm Biopharmaceuticals Limited
Level 15, 500 Collins St
Melbourne, Victoria 3000
USA
Paradigm Biopharmaceuticals (USA) Inc
31 West 34th St, 8th Floor
New York, New York 10001
IRELAND
Paradigm Biopharmaceuticals (Ireland)
Limited
Fitzwilliam Hall, Fitzwilliam Place
Dublin 2
paradigmbiopharma.com | info@paradigmbiopharma.com
25 November 2024
Reference: ODIN103673
Ms Abby Macnish
Company Secretary
Paradigm Biopharmaceuticals Limited
Level 1, 45 Clarence Street
Sydney, NSW, 2000
By email: amacnish@paradigmbiopharma.com
Dear Ms Macnish
Paradigm Biopharmaceutics Limited (‘PAR’): Price - Query
ASX refers to the following:
A. The change in the price of PAR’s securities from a low of $0.32 at close on 22 November 2024 to a high of
$0.45 today.
B. The significant increase in the volume of PAR’s securities traded today.
Request for information
In light of this, ASX asks PAR to respond separately to each of the following questions and requests for
information:
1. Is PAR aware of any information concerning it that has not been announced to the market which, if known by
some in the market, could explain the recent trading in its securities?
If the answer to question 1 is “yes”.
(a)
Is PAR relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please
note that the recent trading in PAR’s securities would suggest to ASX that such information may
have ceased to be confidential and therefore PAR may no longer be able to rely on Listing Rule
3.1A. Accordingly, if the answer to this question is “yes”, you need to contact us immediately to
discuss the situation.
(b)
Can an announcement be made immediately? Please note, if the answer to this question is “no”,
you need to contact us immediately to discuss requesting a trading halt (see below).
(c)
If an announcement cannot be made immediately, why not and when is it expected that an
announcement will be made?
2. If the answer to question 1 is “no”, is there any other explanation that PAR may have for the recent trading in
its securities?
3. Please confirm that PAR is complying with the Listing Rules and, in particular, Listing Rule 3.1.
4. Please confirm that PAR’s responses to the questions above have been authorised and approved under its
published continuous disclosure policy or otherwise by its board or an officer of PAR with delegated authority
from the board to respond to ASX on disclosure matters.
ASX Limited [[Listings]]
ASX Customer Service Centre 131 279 | asx.com.au
When and where to send your response
This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in
any event, by no later than 3:30 PM AEDT Monday, 25 November 2024. You should note that if the information
requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall
within the exceptions mentioned in Listing Rule 3.1A, PAR’s obligation is to disclose the information
‘immediately’. This may require the information to be disclosed before the deadline set out in the previous
paragraph and may require PAR to request a trading halt immediately.
Your response should be sent to me by e-mail at ListingsComplianceMelbourne@asx.com.au. It should not be
sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm
that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements
Platform.
Trading halt
If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is “yes” and
an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request
a trading halt in PAR’s securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:
•
the reasons for the trading halt;
•
how long you want the trading halt to last;
•
the event you expect to happen that will end the trading halt;
•
that you are not aware of any reason why the trading halt should not be granted; and
•
any other information necessary to inform the market about the trading halt, or that we ask for.
We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement
of normal trading on the second day after the day on which it is granted. You can find further information about
trading halts in Guidance Note 16 Trading Halts & Voluntary Suspensions.
Suspension
If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in PAR’s
securities under Listing Rule 17.3.
Listing Rules 3.1 and 3.1A
In responding to this letter, you should have regard to PAR’s obligations under Listing Rules 3.1 and 3.1A and also
to Guidance Note 8 Continuous Disclosure: Listing Rules 3.1 – 3.1B. It should be noted that PAR’s obligation to
disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the
questions set out in this letter.
Release of correspondence between ASX and entity
ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence
between us to the market under Listing Rule 18.7A.
Regards
ASX Compliance
2/2
ASX Customer Service Centre 131 279 | asx.com.au
Share your feedback
Discover